We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s radar. Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December ...

Shares of Pfizer rose modestly Tuesday after the drugmaker forecast a drop in revenue and earnings in 2026, driven in part by weaker Covid-19 product sales.Pfizer expects adjusted per-share earnings ...

Dr. Albert Bourla, chairman and CEO of drugmaker Pfizer, says mRNA technology is "extremely well-tested." - Dia Dipasupil/Getty Images Pharmaceutical rivals don’t often come to each other’s defense.

Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the industry and won't let go anytime soon. Even so, Lilly could carve out a niche ...

Pfizer CEO Albert Bourla defended his company’s vaccine business as rhetoric from HHS Secretary Robert F. Kennedy Jr. drives ...

(CNN) — The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the ...

Pfizer CEO Albert Bourla is among those expected at a fundraiser President Trump is attending Friday at his golf club in Bedminster, New Jersey, sources told CBS News. The fundraiser for the pro-Trump ...

Built into the 2026 guidance is a $1.5 billion decline in sales of its COVID products—from an estimated $6.5 billion this ...

Pfizer’s (PFE) ex-CEO Ian Read and ex-CFO Frank D’Amelio have retreated from activist investor Starboard Value’s campaign at the pharmaceutical giant. Guggenheim Securities, which acts as an advisor ...

In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House ...

Pfizer CEO Albert Bourla appeared on ABC's "This Week." Pfizer CEO Albert Bourla said on ABC's "This Week" Sunday it's possible to provide both COVID-19 booster shots as well as doses for people who ...

Matthew Herper covers medical innovation — both its promise and its perils. SAN FRANCISCO — At the end of a roundtable lunch with a group of reporters, Pfizer CEO Albert Bourla became impassioned. He ...